Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [iU]/g; 1 mg/g Ointment, 3.5 g — NDC 61314-0631-36 package photo

Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [iU]/g; 1 mg/g Ointment, 3.5 g

by Sandoz Inc · 3.5 g in 1 TUBE (61314-631-36)
NDC 61314-0631-36
🏷️ FDA NDC (as labeled) 61314-631-36 billing pads the product segment with a zero
Rx only Brand On market Non-controlled
🗂️ Data synced Aug 27, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
Past resolved recalls for this product (1)
Class II · Apr 13, 2022 · Terminated — cGMP deviations: Temperature abuse (Mckesson Medical-Surgical Inc. Corporate Office) · FDA recall D-1102-2022

🆔 Identity & classification

FDA NDC (as labeled) 61314-631-36
Product NDC 61314-631
11-digit billing NDC 61314063136
NCPDP billing unit GM — per gram (weight)
RxCUI 309679
UNII 057Y626693, 19371312D4, 7S5I7G3JQL
Application # NDA050065
SPL Set ID 7f2e3c46-9f39-45e7-99a9-64cc4f6f649d
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1996-02-21
Route OPHTHALMIC
Dosage form OINTMENT
Substance NEOMYCIN SULFATE; POLYMYXIN B SULFATE; DEXAMETHASONE
GPI-14 86309903324210
GPI class Neomycin-Polymyxin-Dexameth
GCN Seq No 048546
GCN 14285
HICL code 003523
Ingredient (HICL) Neomycin/Polymyxin B/Dexametha
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6I
Therapeutic class — specific (HIC3) Eye Antibiotic And Glucocorticoid Combinations
AHFS code 08:12.02.00
AHFS class Aminoglycoside Antibiotics
FDB label name NEOMYC-POLYM-DEXAMET EYE OINTM
FDB brand name Neomycin-Polymyxin-Dexameth
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AT · RLD · RS
Why two NDCs? The FDA registers this code as 61314-631-36 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 61314-0631-36. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerSandoz Inc
Application holderSANDOZ INC
FDA applicationNDA050065 (NDA AUTHORIZED GENERIC)
Labeler code61314
First marketedFeb 1996
Product typeHuman Prescription Drug
Portfolio387 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name NEOMYC-POLYM-DEXAMET EYE OINTM Ingredient Neomycin/Polymyxin B/Dexametha
📖 What it is MedlinePlus · NLM

Dexamethasone reduces the irritation, redness, burning, and swelling of eye caused by chemicals, heat, radiation, infection, allergy, or foreign bodies in the eye. It is sometimes used after eye surgery.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It's actually treating both at once. This product combines a steroid (dexamethasone) to calm inflammation in your eye and two antibiotics (neomycin and polymyxin B) to fight or pre...
  • What exactly is this eye medication treating — is it for an infection or for inflammation?
  • Shake the bottle well before each use — the medication is a suspension and settles if left still. Tilt your head back, pull down your lower lid slightly, and place the drops into t...
  • Tilt your head back and place a finger gently under your eye to pull the lower lid down, forming a small 'V' pocket. Squeeze a small ribbon of ointment — about half an inch — into...
📖 Read our full Dexamethasone / Neomycin / Polymyxin B guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 7EV65EAW6H
    Lanolin is a waxy substance derived from sheep's wool. It's used in medicines as an emollient and skin-conditioning agent to soften formulations and improve spreadability in topical products like creams and ointments.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
  • UNII Z8IX2SC1OH
    Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $2.687 $9.41 / 3.5 g
Medicaid paysCMS SDUD · 12 mo $4.75 $16.62 / 3.5 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $3.294 $2.662
▼ Down 18% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [USP'U]/g; 1 mg/g 24208-0795-35 Bausch 1 tube $2.687 AT Availability likely
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [iU]/g; 1 mg/gthis 61314-0631-36 Sandoz 3.5 g $2.687 AT Availability likely
Maxitrol 3.5 mg/g; 10000 [USP'U]/g; 1 mg/g 00078-0771-01 Novartis 3.5 g AT FDA listed
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [iU]/g; 1 mg/g 50090-4435-00 A-S 3.5 g AT FDA listed
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [USP'U]/g; 1 mg/g 50090-6181-00 A-S 1 tube AT FDA listed
Neomycin and Polymyxin B Sulfates and Dexamethasone 1 mg/g; 3.5 mg/g; 10000 [USP'U]/g 63187-0395-35 Proficient 1 tube FDA listed
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [USP'U]/g; 1 mg/g 63187-0669-35 Proficient 1 tube AT FDA listed
Maxitrol 3.5 mg/g; 10000 [USP'U]/g; 1 mg/g 66758-0070-38 Sandoz 3.5 g AT FDA listed
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [USP'U]/g; 1 mg/g 68071-2428-03 NuCare 1 tube AT FDA listed
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [iU]/g; 1 mg/g 68071-5281-03 NuCare 3.5 g AT FDA listed
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [USP'U]/g; 1 mg/g 68788-8748-03 Preferred 1 tube AT FDA listed
Neomycin and Polymyxin B Sulfates and Dexamethasone 3.5 mg/g; 10000 [iU]/g; 1 mg/g 71205-0330-35 Proficient 3.5 g AT FDA listed
Neo/Poly-B/Dex Ophth Oint 10000 [USP'U]/g; 3.5 mg/g; 1 mg/g 72189-0532-35 Direct_Rx 3.5 g AT FDA listed
Neomycin And Polymyxin B Sulfates And Dexamethasone 3.5 mg/g; 10000 [USP'U]/g; 1 mg/g 80425-0229-01 Advanced 1 tube AT FDA listed
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1996
On the market since
Feb 1996
📍
2026
Currently FDA-listed
30 years listed
🔒
·
Generic approved (availability unconfirmed)
see note
🔒Generic approved by FDA, but pharmacy availability is not confirmed

The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 61314-0631-36, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
46.3K
Units reimbursed last 4 qtrs
164.2K
Gross reimbursed last 4 qtrs
$779.5K
Avg / prescription
$16.83
Avg / unit
$4.7480
Latest quarter Q4 2025
11.7KRx
Medicaid pays / g
$4.7480
gross reimbursed
vs
NADAC / g
$2.6872
acquisition cost
=
Spread
+$2.0608
+77% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
46% FFS 54% MCO
Fee-for-service · 21,410 Rx Managed care · 24,912 Rx
State Medicaid map
Alaska: 305 units · 41.6 per 100k residents AK Maine: 287 units · 20.6 per 100k residents ME Washington: 2,573 units · 32.9 per 100k residents WA Idaho: 357 units · 18.2 per 100k residents ID Montana: 203 units · 17.9 per 100k residents MT North Dakota: 102 units · 13.0 per 100k residents ND Minnesota: 1,267 units · 22.1 per 100k residents MN Wisconsin: 1,169 units · 19.8 per 100k residents WI Michigan: 3,360 units · 33.5 per 100k residents MI New York: 23,811 units · 122 per 100k residents NY Vermont: 63 units · 9.7 per 100k residents VT New Hampshire: 417 units · 29.7 per 100k residents NH Oregon: 1,579 units · 37.3 per 100k residents OR Nevada: 2,944 units · 92.2 per 100k residents NV Wyoming: no data reported WY South Dakota: 86 units · 9.4 per 100k residents SD Iowa: 364 units · 11.4 per 100k residents IA Illinois: 2,755 units · 22.0 per 100k residents IL Indiana: 2,597 units · 37.8 per 100k residents IN Ohio: 3,917 units · 33.2 per 100k residents OH Pennsylvania: 7,119 units · 54.9 per 100k residents PA New Jersey: 5,327 units · 57.3 per 100k residents NJ Massachusetts: 4,083 units · 58.3 per 100k residents MA California: 36,964 units · 94.9 per 100k residents CA Utah: 301 units · 8.8 per 100k residents UT Colorado: 1,082 units · 18.4 per 100k residents CO Nebraska: 326 units · 16.5 per 100k residents NE Missouri: 1,522 units · 24.6 per 100k residents MO Kentucky: 1,722 units · 38.0 per 100k residents KY West Virginia: 574 units · 32.4 per 100k residents WV Virginia: 5,772 units · 66.2 per 100k residents VA Maryland: 2,903 units · 47.0 per 100k residents MD Connecticut: 3,623 units · 100 per 100k residents CT Rhode Island: 1,390 units · 127 per 100k residents RI Arizona: 4,386 units · 59.0 per 100k residents AZ New Mexico: 949 units · 44.9 per 100k residents NM Kansas: 347 units · 11.8 per 100k residents KS Arkansas: 956 units · 31.2 per 100k residents AR Tennessee: 1,187 units · 16.7 per 100k residents TN North Carolina: 5,012 units · 46.3 per 100k residents NC South Carolina: 1,883 units · 35.0 per 100k residents SC Delaware: 371 units · 36.0 per 100k residents DE Oklahoma: 1,358 units · 33.5 per 100k residents OK Louisiana: 2,237 units · 48.9 per 100k residents LA Mississippi: 639 units · 21.7 per 100k residents MS Alabama: 1,099 units · 21.5 per 100k residents AL Georgia: 2,923 units · 26.5 per 100k residents GA D.C.: 512 units · 75.4 per 100k residents DC Hawaii: 1,147 units · 79.9 per 100k residents HI Texas: 8,729 units · 28.6 per 100k residents TX Florida: 9,058 units · 40.1 per 100k residents FL
Units reimbursed · per 100k residents
8.8127
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Rhode Island 127 /100k
2 New York 122 /100k
3 Connecticut 100 /100k
4 California 94.9 /100k
5 Nevada 92.2 /100k
6 Hawaii 79.9 /100k
7 D.C. 75.4 /100k
8 Virginia 66.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE — the ingredient across all brands.

Top reported reactions

Eye Irritation40
Vision Blurred26
Ocular Hyperaemia23
Eye Pain21
Condition Aggravated14
Hypersensitivity12
Visual Impairment11

Age at onset

Child1
Adult5
Elderly7

Reporter sex

200 reports
Male · 28%
Female · 71%
Unknown · 1%

Serious outcomes

Hospitalization6
Death3
Life-threatening2
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 33 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
61314-0631-36 You're viewing this 3.5 g in 1 TUBE (61314-631-36) 1996-02-21 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 171 words

INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and Streptococci , including Streptococcus pneumoniae.

⏱️ Dosage and Administration 144 words

DOSAGE AND ADMINISTRATION Apply a small amount into the conjunctival sac(s) up to three or four times daily, or may be used adjunctively with Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension at bedtime. How to Apply Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment: 1. Tilt your head back.

2. Place a finger on your cheek just under your eye and gently pull down until a "V" pocket is formed between your eyeball and your lower lid. 3.

Place a small amount (about 1/2 inch) of neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment in the "V" pocket. Do not let the tip of the tube touch your eye. 4.

Look downward before closing your eye. Not more than 8 g should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.

Contraindications 80 words

CONTRAINDICATIONS Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment is contraindicated in epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular structures.

Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment is also contraindicated in individuals with known or suspected hypersensitivity to a component of the medication. (Hypersensitivity to the antibiotic component occurs at a higher rate than for other components.)

⚠️ Warnings ~1 min read

WARNINGS NOT FOR INJECTION. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of steroid medication in the treatment of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.

Prolonged use may result in glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions or parasitic infections of the eye, steroids may mask infection or enhance existing infection.

In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. If this product is used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma.

IOP should be checked frequently. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Products containing neomycin sulfate may cause cutaneous sensitization.

Sensitivity to topically administered aminoglycosides, such as neomycin, may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If hypersensitivity develops during use of the product, treatment should be discontinued.

Cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.

🤒 Adverse Reactions 214 words

ADVERSE REACTIONS Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available. Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations.

The reactions due to the steroid component are: elevation of IOP with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. Secondary Infection: The development of secondary infection has occurred after use of combinations containing steroids and antimicrobials. Fungal infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroid.

The possibility of fungal invasion must be considered in any persistent corneal ulceration where steroid treatment has been used. Keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following use of steroids. Secondary bacterial ocular infection following suppression of host responses also occurs.

Additional adverse reactions identified from post marketing use include ulcerative keratitis, headache, and Stevens-Johnson syndrome. The following additional adverse reactions have been reported with dexamethasone use: Cushing’s syndrome and adrenal suppression may occur after use of dexamethasone in excess of the listed dosing instructions in predisposed patients, including children and patients treated with CYP3A4 inhibitors.

🧬 Clinical Pharmacology 134 words

CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case. When a decision to administer both a corticosteroid and an antimicrobial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered, plus assured compatibility of ingredients when both types of drugs are in the same formulation and, particularly, that the correct volume of drug is delivered and retained.

The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.

📦 How Supplied / Storage and Handling 87 words

HOW SUPPLIED Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment is supplied as a STERILE ointment in an aluminum tube with a white polyethylene tip and white polyethylene cap as follows: 3.5 g in an aluminum tube NDC 61314-631-36 Storage: Store at 2°C to 25°C (36°F to 77°F). After opening, neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment can be used until the expiration date on the tube. Manufactured by Novartis Manufacturing NV Puurs-Sint-Amands, Belgium for Sandoz Inc., Princeton, NJ 08540 Rev.

07/2024 9103458 US

📋 Description 144 words

DESCRIPTION Neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment is a multiple dose anti-infective steroid combination in sterile ointment form for topical application. The chemical structure for the active ingredient Neomycin Sulfate is: Neomycin B (R 1 =H, R 2 =CH 2 NH 2 ) Neomycin C (R 1 =CH 2 NH 2 , R 2 =H) The chemical structure for the active ingredient Polymyxin B Sulfate is: The chemical structure for the active ingredient Dexamethasone is: C 22 H 29 FO 5 Molecular Weight = 392.47 g/mol Established name: dexamethasone Chemical name: pregna-1, 4-diene-3, 20-dione,9-fluoro-11,17, 21-trihydroxy-16-methyl-, (11β, 16α)-.

Each gram of neomycin and polymyxin B sulfates and dexamethasone ophthalmic ointment contains: Active: neomycin sulfate equivalent to neomycin 3.5 mg, polymyxin B sulfate 10,000 units, dexamethasone 0.1%. Preservatives: methylparaben 0.05%, propylparaben 0.01%. Inactives: anhydrous liquid lanolin and white petrolatum. neomycin-chemical polymyxin-chemical polymyxin-text dexamethasone-chemical

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.